Thus, PJA2 emerges as a multifaceted target, with implications not only for direct tumor suppression but also for modulating the tumor's interaction with the host's immune system, offering a promising avenue for the development of personalized and combinatorial cancer treatments. The gene discussed is PJA2; the disease is cancer.